Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
CONSTELLATION PHARMACEUTICALS INC (CNST) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/13/2020 8-K Investor presentation
Docs: "Presentation (furnished herewith)"
09/24/2019 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : September 24, 2019 Constellation Pharmaceuticals, Inc. Delaware 001-38584 26-1741721 215 First Street, Suite 200 Cambridge, Massachusetts 02142 Registrant's telephone number, including area code: 714-0555 Not applicable",
"900 800 700 600 500"
08/07/2019 8-K Investor presentation
Docs: "Constellation Pharmaceuticals Announces Second-Quarter and Six-Month 2019 Financial Results",
"Corporate Overview (furnished herewith)"
05/16/2019 8-K Investor presentation
Docs: "Constellation Pharmaceuticals Provides Interim Update of Data for CPI-0610 in ASCO and EHA Abstracts",
"Corporate Overview (furnished herewith)",
"Abstract published by EHA titled CPI-0610, a BromoDomain and Extraterminal Domain (BET) Inhibitor, Reduces Pro-Inflammatory Cytokines, Bone Marrow Fibrosis and the Number of Transfusions in Myelofibrosis Patients (furnished herewith)"
05/08/2019 8-K Investor presentation
Docs: "Constellation Pharmaceuticals Announces First-Quarter 2019 Financial Results",
"Corporate Overview dated May 2019 (furnished herewith)"
04/01/2019 8-K Investor presentation
Docs: "Constellation Pharmaceuticals Presents Results from Phase 1b Portion of ProSTAR Clinical Trial of CPI-1205 at AACR Meeting",
"Corporate Overview dated April 2019 (furnished herewith)"
03/14/2019 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : March 14, 2019 Constellation Pharmaceuticals, Inc. Delaware 001-38584 26-1741721 215 First Street, Suite 200 Cambridge, Massachusetts 02142 Registrant's telephone number, including area code: 714-0555 Not applicable",
"Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2018 Financial Results CAMBRIDGE, Massachusetts, March 14, 2019 - Constellation Pharmaceuticals , Inc. , a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its fourth-quarter and full-year 2018 financial results. “2019 is a year of data for Constellation, and our clinical programs are making significant progress and approaching important readouts,” said Jigar Raythatha, president and chief executive officer of Constellation Pharmaceuticals. “We are excited by preliminary data from our first four patients from the MANIFEST clinical trial, each showing one or more of the following: conversion from transfusion dependence to transfusion ind...",
"Corporate Overview dated March 2019"
01/07/2019 8-K Investor presentation
Docs: "Corporate Overview dated January 2019 (furnished herewith)",
"Corporate Overview dated January 2019 (furnished herewith)"
12/10/2018 8-K Investor presentation
Docs: "FORM 8-K",
"Constellation Pharmaceuticals Initiates Phase 2 Portion of ProSTAR Clinical Trial in Patients with Metastatic Castration-Resistant Prostate Cancer • Dosing has begun in a randomized study of CPI-1205 / enzalutamide combination versus enzalutamide alone in second-line mCRPC • Single-arm CPI-1205 / abiraterone / prednisone combination added to potentially address low response rates and short duration of response in second-line mCRPC with abiraterone alone • Preliminary Phase 1b results suggest CPI-1205 is well-tolerated, with a robust PK/PD profile and clinical activity in both arms in second-line mCRPC CAMBRIDGE, Massachusetts, December 10, 2018 - Constellation Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel...",
"Corporate Overview dated December 2018 (furnished herewith)"
10/10/2018 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : October 10, 2018 Constellation Pharmaceuticals, Inc. Delaware 001-38584 26-1741721 215 First Street, Suite 200 Cambridge, Massachusetts 02142 Registrant's telephone number, including area code: 714-0555 Not applicable",
"Constellation Pharmaceuticals Enhances and Expands Phase 2 MANIFEST Study of CPI-0610 in Myelofibrosis - Amends second-line trial design to stratify for transfusion dependence based on positive preliminary data - - Expands study to include an additional arm evaluating CPI-0610 as first-line therapy in combination with ruxolitinib in JAK-inhibitor-naïve myelofibrosis patients - - Maintains prior guidance for determining proof of concept by mid-2019 - - Company to host conference call at 8:30 AM EDT on Thursday, October 11 - CAMBRIDGE, Massachusetts, October 10, 2018 - Constellation Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced several planned updates to the Phase 2 portio...",
"Corporate Overview dated October 2018 (furnished herewith)"
08/14/2018 8-K Investor presentation, Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : August 14, 2018 Constellation Pharmaceuticals, Inc. Delaware 001-38584 26-1741721 215 First Street, Suite 200 Cambridge, Massachusetts 02142 Registrant's telephone number, including area code: 714-0555 Not applicable",
"Constellation Pharmaceuticals Announces Second-Quarter and Six-Month 2018 Financial Results",
"Corporate Overview dated August 2018"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy